Medtronic InFuse Bone Graft Is “Approvable” For Oral Use – FDA Dental Panel

A possible reduction in morbidity associated with use of Medtronic's InFuse bone graft compared with conventional autograft treatment for oromaxillofacial bone defects outweighs potentially reduced efficacy of up to 20% and justifies FDA approval, the agency's Dental Products Panel agreed Nov. 9